Department of Disease Surveillance, Control and Research, Ministry of Health, Ndeke House, P. O. Box 30205, Lusaka, Zambia.
Centre of Tropical Medicine and Travel Medicine, Division of Internal Medicine, Department of Infectious Diseases, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Infection. 2017 Dec;45(6):831-839. doi: 10.1007/s15010-017-1054-8. Epub 2017 Aug 4.
The purpose of this study was to establish a baseline for measuring the impact of the programmatic management of drug-resistant TB program by following up on outcomes of all patients diagnosed with multidrug-resistant tuberculosis in Zambia between 2012 and 2014.
A cohort study of all the MDR-TB patients diagnosed at the national TB reference laboratory from across Zambia. MDR-TB was diagnosed by culture and DST, whereas outcome data were collected in 2015 by patient record checks and home visits.
The total number of patients diagnosed was 258. Of those, 110 (42.6%) patients were traceable for this study. There were 67 survivor participants (60.9%); 43 (39.1%) were deceased. Out of the 110 patients who were traced, only 71 (64.5%) were started on second-line treatment. Twenty-nine (40.8%) patients were declared cured and 16.9% were still on treatment; 8.4% had failed treatment. The survival rate was 20.2 per 100 person-years of follow-up. Taking ARVs was associated with a decreased risk of dying (hazard ratio 0.12, p = 0.002). Sex, age, marital status and treatment category were not important predictors of survival in MDR-TB patients.
More than half of the patients diagnosed with MDR-TB were lost to follow-up before second-line treatment was initiated.
本研究旨在通过跟踪 2012 年至 2014 年间赞比亚所有耐多药结核病患者的结局,为耐药结核病规划管理建立衡量该规划影响的基线。
对来自赞比亚各地国家结核病参考实验室诊断的所有耐多药结核病患者进行队列研究。耐多药结核病的诊断依据是培养和药敏试验,而结局数据则于 2015 年通过患者病历检查和家访收集。
共诊断出 258 例患者。其中,110 例(42.6%)患者可追踪到此项研究。有 67 例存活参与者(60.9%);43 例(39.1%)死亡。在追踪到的 110 例患者中,仅有 71 例(64.5%)开始二线治疗。29 例(40.8%)患者治愈,16.9%仍在治疗中;8.4%治疗失败。随访期间的生存率为每 100 人年 20.2 人。服用抗逆转录病毒药物与降低死亡风险相关(风险比 0.12,p=0.002)。性别、年龄、婚姻状况和治疗类别不是耐多药结核病患者生存的重要预测因素。
在开始二线治疗之前,超过一半的耐多药结核病患者失访。